Numerate Forms Drug Discovery Collaboration with Merck to Utilize Numerate’s In Silico Drug Design Technology

I am proud to announce our latest partnership with Merck.  This collaboration is another sign that our business and technology continue to grow.

Numerate Forms Drug Discovery Collaboration with Merck to Utilize Numerate’s In Silico Drug Design Technology; Research to Focus on Cardiovascular Disease Target

SAN BRUNO, CA – March 14, 2012Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that it has entered into a research collaboration with Merck, through a subsidiary. The collaboration will utilize Numerate’s proprietary in silico drug design technology to generate novel small molecule drug leads for an undisclosed cardiovascular disease target.

“We are pleased to add Merck, a recognized leader in drug discovery innovation, to our growing number of pharmaceutical collaborators,” stated Numerate chief executive officer Guido Lanza.  “This collaboration is focused on increasing the speed, cost-efficiency and likelihood of generating new small molecule drug leads through the use of our large-scale computational drug design methods.”

Numerate’s drug design platform features a set of proprietary algorithms that provide predictive models for molecular properties with accuracies comparable to laboratory testing.  Used in conjunction with cloud computing, these algorithms enable Numerate scientists to search through spaces of billions of compounds to rapidly and efficiently identify those with the highest probability of activity against a specific target.